NeuroPace, Inc. (NPCE) shares dropped 33.7 percent to $11.73 on Tuesday, falling $5.95 after the company announced mixed one-year results from its NAUTILUS study evaluating the RNS System for drug-resistant idiopathic generalized epilepsy.
NPCE opened at $13.37 and traded between $10.63 and $14.75 during the session on the Nasdaq. Volume surged to 648,450 shares, well above the average of 246,673. The stock closed at $17.68 in the previous session.
Over the past 52 weeks, NeuroPace has traded between $5.45 and $18.98.
While the study met its 12-week post-implant safety endpoint with a low rate of serious adverse events, it failed to reach statistical significance for the primary effectiveness endpoint in the overall population.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.